Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

To join this study, you must have advanced non-small cell lung cancer (Stage IV) with a specific genetic change called KRASG12C. Your doctor will have already checked for this. You should also have tried at least one other cancer treatment before. You need to be at least 18 years old, and the study is particularly looking for people aged 70 or older, or those who have some health challenges that mean they aren't quite as active as they used to be.

There are also some general health checks. You need to be expected to live for at least 12 more weeks, and your body's organs like your blood, kidneys, and liver need to be working well enough. If you can get pregnant, you'll need to use reliable contraception throughout the study, and have a negative pregnancy test before starting.

You cannot join if you've already had a similar drug that targets KRASG12C, or if you've recently been in another drug trial. You also can't participate if you have untreated cancer spread to your brain or the lining around it, or if you have certain serious heart problems or stomach issues that might stop you from taking the medication properly.

If you join the ADEPPT study, you will take the study drug, adagrasib, as a pill twice a day. This will continue until your cancer starts to grow again, or if you experience side effects that make it too difficult to continue. You will have regular visits to the clinic to check on your health and how the treatment is working. This will involve physical exams, blood tests, and scans to see if your tumour has shrunk. The study team will monitor you closely for any side effects and to make sure you are managing your treatment well. The total length of your participation will depend on how you respond to the treatment and your overall health, and you would need to be able to attend all scheduled appointments.